13 November, 2017 by The TZ Newswire Staff Comments Off on Endeavour Makes New Discoveries at both its Houndé and Karma Mines
Endeavour Makes New Discoveries at both its Houndé and Karma Mines
ENDEAVOUR MAKES NEW DISCOVERIES
AT BOTH ITS HOUNDÉ AND KARMA MINES
13 November, 2017 by The TZ Newswire Staff Comments Off on Endeavour Makes New Discoveries at both its Houndé and Karma Mines
Endeavour Makes New Discoveries at both its Houndé and Karma Mines
ENDEAVOUR MAKES NEW DISCOVERIES
AT BOTH ITS HOUNDÉ AND KARMA MINES
13 November, 2017 by The TZ Newswire Staff Comments Off on Wall Street bonuses jump 10% under Trump, but employee wages are stagnant
Wall Street bonuses jump 10% under Trump, but employee wages are stagnant
Most Americans are still waiting on a bigger salary.
read more
13 November, 2017 by The TZ Newswire Staff Comments Off on Propel Media Reports $22.2 Million in Sales and $8.7 Million of Adjusted EBITDA for the 3rd Quarter of 2017
Propel Media Reports $22.2 Million in Sales and $8.7 Million of Adjusted EBITDA for the 3rd Quarter of 2017
3rd Quarter of 2017 Adjusted EBITDA up 42% Compared to 3rd Quarter of 2016
13 November, 2017 by The TZ Newswire Staff Comments Off on Propel Media Reports $22.2 Million in Sales and $8.7 Million of Adjusted EBITDA for the 3rd Quarter of 2017
Propel Media Reports $22.2 Million in Sales and $8.7 Million of Adjusted EBITDA for the 3rd Quarter of 2017
3rd Quarter of 2017 Adjusted EBITDA up 42% Compared to 3rd Quarter of 2016
13 November, 2017 by The TZ Newswire Staff Comments Off on Endeavour Makes New Discoveries at both its Houndé and Karma Mines
Endeavour Makes New Discoveries at both its Houndé and Karma Mines
ENDEAVOUR MAKES NEW DISCOVERIES
AT BOTH ITS HOUNDÉ AND KARMA MINES
13 November, 2017 by The TZ Newswire Staff Comments Off on Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company’s lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced the grant of an accelerated assessment from the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR (hATTR) amyloidosis.